Trial reportBlood2017
Long-term outcome of acute promyelocytic leukemia treated with all-
5 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 141 papers.
0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
A Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of Arsenic Trioxide for Injection in Patients With Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation
Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia
NCT06199557 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation
A Phase 1/2 Multicenter Open-label Study to Investigate Treatment of Hydroxyurea in Combination With Valproic Acid (VPA), or 6- Mercaptopurine in Combination With VPA in Patients With AML or HR-MDS Unfit for Standard Therapy
Who cites it
141 citing papers in PubMed, 295 citations in OpenAlex.
- Trial
- An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).Blood cancer journal · 2022Trial
- Arsenic Combined With All-Trans Retinoic Acid for Pediatric Acute Promyelocytic Leukemia: Report From the CCLG-APL2016 Protocol Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study.Journal of cancer research and clinical oncology · 2021Trial
- Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).Proceedings of the National Academy of Sciences of the United States of America · 2021Trial
- A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).Blood advances · 2020Trial
- A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.Cancer medicine · 2020Trial
- Trial
- Trial
- Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.Haematologica · 2018Trial
- Trial
- Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework.Biomolecules · 2026Review
- The promyelocytic leukemia PML protein coordinates immune evasion in triple-negative breast cancer via independent and converging mechanisms.Cell death and differentiation · 2026Article
- Treatment Outcomes and Factors Affecting Survival in Pediatric Acute Myeloid Leukemia.Annals of hematology · 2026Article
- Multicenter validation of an explainable machine-learning model for APL, AMoL, and ALL.Frontiers in oncology · 2026Article
- Establishment and validation of a 28-day clinical outcome prediction model for acute promyelocytic leukemia based on an early platelet-coagulation factor combined transfusion strategy.American journal of cancer research · 2026Article
- The Expendables: Overlooked Medications with Anti-Cancer Properties.Current oncology reports · 2025Review
- Patients with high-risk acute promyelocytic leukemia need maintenance therapy for 1 year - the PROS.Haematologica · 2025Article
- [The cure for acute promyelocytic leukemia and China's contributions].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.Blood advances · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 4 institutions in 1 country.
Yasmin AbazaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-9156-7912
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1908-3307
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Elihu EsteyDepartment of Hematology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA.ORCID 0000-0002-0987-8077
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7679-6453
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Stefan FaderlDepartment of Hematology/Oncology, Hackensack University Medical Center, Hackensack, NJ.
Susan O'BrienDepartment of Hematology/Oncology, University of California, Irvine, CA.
William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sherry PierceDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Mark BrandtDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Deborah McCueDepartment of Pharmacy, and.
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Keyur PatelDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Steven KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Tapan KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Courtney DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alessandra FerrajoliDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Zeev EstrovDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Maria FoudrayDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
David McCueDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jorge CortesDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USHackensack University Medical Center · USUniversity of California, Irvine · USUniversity of Washington · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MNCI NIH HHS P30 CA016672
Abstract
The combination of all-
Indexed as
AdolescentAdultAgedAged, 80 and overAminoglycosidesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsArsenicalsArsenic TrioxideDisease-Free SurvivalFemaleFollow-Up StudiesGemtuzumabHumansKaplan-Meier EstimateLeukemia, Promyelocytic, AcuteAminoglycosidesAntibodies, Monoclonal, HumanizedArsenicalsArsenic TrioxideGemtuzumabOxidesTretinoin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03980665ClinicalTrials.gov
NCT04251754ClinicalTrials.gov
NCT04489706ClinicalTrials.gov
NCT04687176ClinicalTrials.gov
NCT06199557ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.